We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+23%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
-$697M
Cap. Flow
-$415M
Cap. Flow %
-21.46%
Top 10 Hldgs %
57.89%
Holding
87
New
13
Increased
14
Reduced
17
Closed
30

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$87.5M
2
SPTX
Seaport Therapeutics
SPTX
+$62.7M
3
GILD icon
Gilead Sciences
GILD
+$45.2M
4
ANAB icon
AnaptysBio
ANAB
+$14.9M
5
ABT icon
Abbott
ABT
+$11.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$89.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$63.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$51M
4
UTHR icon
United Therapeutics
UTHR
+$47.1M
5
BIIB icon
Biogen
BIIB
+$42.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.78%
2 Miscellaneous 3.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
26
BioMarin Pharmaceuticals
BMRN
$12.7B
$20.5M 1.06%
358,568
-423,414
-54% -$23.2M
MANE
27
Veradermics Inc
MANE
$4.17B
$18.3M 0.95%
148,993
+75,678
+103% +$7.09M
ALC icon
28
Alcon
ALC
$31.9B
$17.2M 0.89%
255,824
-474,148
-65% -$33.2M
INSM icon
29
Insmed
INSM
$28.3B
$16.9M 0.87%
158,398
-187,677
-54% -$22.7M
RARE icon
30
CALL
Ultragenyx Pharmaceutical
RARE
$1.42B
$16.7M 0.86%
500,000
+150,000
+43% +$3.73M
ISRG icon
31
CALL
Intuitive Surgical
ISRG
$131B
$15.9M 0.82%
+40,000
New +$17.5M
GMED icon
32
CALL
Globus Medical
GMED
$9.96B
$15.8M 0.82%
+200,000
New +$17M
EWTX icon
33
Edgewise Therapeutics
EWTX
$4.86B
$15.5M 0.8%
380,923
-5,575
-1% -$192K
EXEL icon
34
PUT
Exelixis
EXEL
$14B
$13.8M 0.72%
254,200
+2,700
+1% +$131K
NRIX icon
35
Nurix Therapeutics
NRIX
$2.63B
$12.7M 0.66%
+524,098
New +$8.93M
DSGN icon
36
Design Therapeutics
DSGN
$912M
$12.5M 0.65%
+865,135
New +$10.8M
DFTX
37
Definium Therapeutics
DFTX
$5.26B
$12M 0.62%
255,903
-88,263
-26% -$2.18M
TRAX
38
First Tracks Biotherapeutics
TRAX
$1.28B
$11.4M 0.59%
+565,199
New +$10.6M
ABT icon
39
Abbott
ABT
$177B
$11.2M 0.58%
+122,998
New +$11.2M
IRON icon
40
Disc Medicine
IRON
$2.67B
$10.7M 0.55%
146,239
+67,919
+87% +$4.67M
TENX icon
41
Tenax Therapeutics
TENX
$70.4M
$7.28M 0.38%
500,039
+395,639
+379% +$5.05M
SION
42
Sionna Therapeutics
SION
$346M
$6.35M 0.33%
+144,432
New +$5.78M
ABSI icon
43
Absci
ABSI
$1.41B
$3.91M 0.2%
+337,400
New +$1.9M
MIRM icon
44
Mirum Pharmaceuticals
MIRM
$6.38B
$3.23M 0.17%
27,591
– –
JBIO
45
Jade Biosciences
JBIO
$1.13B
$2.39M 0.12%
107,391
– –
SVRA icon
46
Savara
SVRA
$1.1B
$2.25M 0.12%
364,763
– –
PRAX icon
47
Praxis Precision Medicines
PRAX
$9.4B
$2.16M 0.11%
6,440
-57,240
-90% -$18.1M
SEPN
48
Septerna Inc
SEPN
$1.8B
$1.59M 0.08%
47,506
– –
OKUR
49
OnKure Therapeutics
OKUR
$127M
$1.47M 0.08%
321,692
+179,992
+127% +$772K
SGMT icon
50
Sagimet Biosciences
SGMT
$676M
$1.29M 0.07%
+166,667
New +$1.13M
1
2
3 4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Sofinnova Investments held 87 positions worth $1.93B, down 26% from $2.63B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments withdrew a net $415M in Q2 2026, closing 30 positions and reducing 17 holdings. Its most notable exit was AstraZeneca, an estimated $89.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, Sofinnova Investments opened a new position in Seaport Therapeutics worth $77.4M.

  • Sofinnova Investments's largest Q2 2026 buy was Seaport Therapeutics: 3,564,871 shares worth $77.4M.
  • Sofinnova Investments added most to Genmab in Q2 2026, an estimated $87.5M increase.
  • Sofinnova Investments's biggest Q2 2026 reduction was Bristol-Myers Squibb, cutting an estimated $63.8M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2026, selling an estimated $89.9M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.93B portfolio in Q2 2026.
  • Sofinnova Investments opened 13 new positions and closed 30 in Q2 2026.
  • Sofinnova Investments's portfolio value fell 26% quarter-over-quarter to $1.93B.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.